Mitochem therapeutics inc
Web23 feb. 2024 · MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was founded to develop a new approach to treating neurodegeneration and aging diseases by focusing on protecting mitochondrial homeostasis. WebLegal Name MitoChem Therapeutics, Inc. Company Type For Profit Contact Email [email protected] Phone Number 520-204-5552 MitoChem Therapeutics …
Mitochem therapeutics inc
Did you know?
Web16 mrt. 2024 · SCRA: South Carolina Research Authority — SC Launch Inc. Announces Investment in MitoChem Therapeutics Funding Round • Sep 6, 2024 MitoChem Therapeutics raised $200,000 / Series Unknown from SC Launch, Inc. Web14 apr. 2024 · CHARLESTON, SC / ACCESSWIRE / April 14, 2024 / MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today that...
WebMitoChem Therapeutics became an SCRA Member Company in 2024 and received a $25,000 Academic Startup Grant. The company became an SC Launch Inc. Portfolio Company with a $200,000 investment in August of 2024. MitoChem has also been a long-term tenant at SCRA’s Innovation Center in Charleston. Web6 sep. 2024 · MitoChem Therapeutics became an SCRA Member Company in 2024 and received a $25,000 Academic Startup Grant. It became an SC Launch Inc. Portfolio Company with this investment. MitoChem has also been a long-term tenant at SCRA’s Innovation Center in Charleston.
Web30 dec. 2024 · Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2024’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of … Web15 feb. 2024 · www.mitocheminc.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Biotechnology Other Industries Drug Discovery Primary Office Franklin Street Charleston, SC 29401 United States +1 (520) 000-0000 MitoChem Therapeutics Timeline 2024 2024 2024 2024
Web...PDUFA goal of Aug. 12.MitoChem gains orphan award in retinitis pigmentosa FDA granted orphan drug designation to MitoChem Therapeutics Inc. ’s.....govitecan (hRS7 …
WebGeneral information We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition. Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on … reincarnation magician inferior eyesWeb23 feb. 2024 · MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced that Bärbel Rohrer Ph.D., CSO, will present at the Mitochondrial-Targeted Drug Development Summit on Thursday, February 24, 2024 at 11:30am ET. procurement in the uk construction industryWeb23 feb. 2024 · MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was founded to develop a … reincarnation makes no senseWebMitochem Therapeutics Inc. Mitochem Therapeutics LLC. Revenue. $1.3 M. Employees. 3. Primary Industries. Business Services Research & Development. CEO Michael Voevodsky . Recently Updated Team Members. Name & Title Social Contact Info; Richard Comer. Chemist. Reveal for Free. Top MitoChem Therapeutics Integrations and … procurement in value chain analysisWeb15 feb. 2024 · The company addresses eye-related diseases such as retinitis pigmentosa, age-related macular degeneration, and glaucoma by focusing on protecting … reincarnation male oc fanfictionWebMitoChem Therapeutics has raised a total of $3.7M in funding over 4 rounds. Their latest funding was raised on Sep 6, 2024 from a Venture - Series Unknown round. MitoChem … reincarnation manga readWebMitoChem Therapeutics is a privately held company developing mitochondrial targeted small molecules for ophthalmic and neurodegenerative diseases. MitoChem has developed a new class of small molecules designed to treat neurodegeneration by protecting the powerhouse of the cell: mitochondria. reincarnation meme